


Claims

## 1. Use of



5

wherein  $R_0 = O, CH_2$  or S

and

$-R_1 =$   $-CH_2CH_3$  (ethyl), or  
 $-CH_2CH_2CH_3$  (n-propyl), or  
 $-CH_2CH_2CH_2COOH$  (3-carboxypropyl), or  
 $-CH_2CH_2CH_2CHO$  (4-oxobutyl), or  
 $-CH_2CH_2CH_2CH_3$  (n-butyl), or  
 $-CH_2CH_2CH_2CF_3$  (4,4,4-trifluorobutyl), or  
 $-CH_2CH_2CH_2CH_2OH$  (4-hydroxybutyl), or  
 $-CH_2CH_2CH_2CH_2CHO$  (5-oxopentyl), or  
 $-CH_2CH_2CH_2CH_2CH_3$  (n-pentyl), or  
 $-CH_2CH_2CH_2CH_2CF_3$  (5,5,5-trifluoropentyl), or  
 $-CH_2CH_2CH_2CH_2COOH$  (4-carboxybutyl), or  
 $-CH_2CH_2CH_2CH_2NH_2$  (4-aminobutyl), or  
 $-C_6H_{11}OH$  (4-hydroxycyclohexyl), or  
 $-C_6H_{11}CF_3$  (4-trifluoromethylcyclohexyl), or  
 $-C_6H_5$  (phenyl), or  
 $-C_6H_4OH$  (p-hydroxyphenyl), or  
 $-C_6H_4NH_2$  (p-aminophenyl), or  
 $-C_6H_4NO_2$  (p-nitrophenyl), or  
 $-C_6H_4COOH$  (p-carboxyphenyl), or  
 $-C_6H_4CH_3$  (p-methylphenyl), or  
 $-C_6H_4CF_3$  (p-trifluoromethylphenyl), or  
 $-C_6H_4CHO$  (p-formylphenyl), or  
 $-C_4H_5N_2$  (pyrimidyl), or  
 $-C_4H_4N_2OH$  (2-hydroxypyrimidyl), or  
 $-C_6H_{11}$  (cyclohexyl)

10 for the manufacture of a medicament to treat a subject suffering from infection of a Gram-negative bacterium.

2. Use according to claim 1 for the manufacture of a medicament to treat a subject suffering from infection of a Gram-negative bacterium wherein said bacterium comprises a type-1 pilus.

3. Use of a molecule according to claims 1 and 2 wherein said bacterium is selected from the list consisting of *Klebsiella pneumoniae*, *Haemophilus influenza*, *Shigella* species, *Salmonella typhimurium*, *Bordetella pertussis*, *Yersinia enterocolitica*, *Helicobacter pylori*, *Proteus* species and *Escherichia coli*.
- 5 4. Use of a molecule according to claim 1 for the manufacture of a medicament to treat a urinary infection.
5. Use according to claim 4 wherein said urinary infection is caused by *E. coli*.
6. Use of a molecule according to claim 1 for the manufacture of a medicament to treat a gastrointestinal infection.
- 10 7. Use according to claim 6 wherein said gastrointestinal infection is caused by *Escherichia*, *Salmonella*, *Shigella* or *Yersinia* species.
8. Use of a molecule according to claim 1 for the manufacture of a medicament to treat a pulmonary infection.
9. Use according to claim 8 wherein said pulmonary infection is caused by *Haemophilus*
- 15 *influenzae*, *Bordetella pertussis* or *Klebsiella* species.